IPH5201 + Durvalumab + Chemotherapy for Lung Cancer
Trial Summary
What is the purpose of this trial?
The study is intended to assess the safety and efficacy of neoadjuvant combination of IPH5201 and durvalumab in addition to standard chemotherapy and adjuvant combination of IPH5201 and durvalumab in untreated patients with resectable, early-stage (stage II to IIIA) non-small cell lung cancer (NSCLC).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot take any other chemotherapy, investigational drugs, or immunosuppressive medications during the study.
What data supports the effectiveness of the drug combination IPH5201, Durvalumab, and chemotherapy for lung cancer?
Research shows that Durvalumab, when used alone or with chemotherapy, improves survival in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). It is particularly effective as a maintenance therapy after chemoradiotherapy in NSCLC and has shown significant survival benefits in combination with chemotherapy in SCLC.12345
Is the combination of IPH5201, Durvalumab, and chemotherapy generally safe for humans?
Durvalumab, a part of this treatment, has been shown to have a manageable safety profile in lung cancer patients, but it can cause immune-related side effects like pneumonitis (lung inflammation), which can be serious. About 25% of patients in a study experienced immune-related side effects, with 3.4% having severe reactions.12678
What makes the drug combination of IPH5201, Durvalumab, and chemotherapy unique for lung cancer?
This treatment combines Durvalumab, an immune checkpoint inhibitor that blocks PD-L1 to help the immune system attack cancer cells, with IPH5201, a novel antibody targeting CD39, and standard chemotherapy. This combination aims to enhance the immune response against lung cancer, potentially offering a new approach for patients who may not respond well to existing treatments.124910
Eligibility Criteria
This trial is for patients with early-stage (II to IIIA) non-small cell lung cancer that can be surgically removed. They must have proper organ function, not be pregnant, and agree to use contraception. Excluded are those with small-cell lung cancer, certain genetic mutations, autoimmune diseases, another primary malignancy, or severe cardiovascular disease.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Neoadjuvant Treatment
Participants receive neoadjuvant therapy with IPH5201 and durvalumab in addition to standard chemotherapy before surgery
Surgery
Participants undergo surgical resection
Adjuvant Treatment
Participants receive adjuvant treatment with IPH5201 and durvalumab post-surgery
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Durvalumab
- IPH5201
- Standard Chemotherapy
Durvalumab is already approved in European Union, United States, Japan for the following indications:
- Locally advanced, unresectable non-small cell lung cancer (NSCLC)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Limited-stage small cell lung cancer (LS-SCLC)
- Locally advanced or metastatic urothelial carcinoma
- Not specified in provided sources
Find a Clinic Near You
Who Is Running the Clinical Trial?
Innate Pharma
Lead Sponsor